News | May 03, 2021
Gujarat Themis Biosyn Q4FY21 net profit lower at Rs. 5.79 Cr
Gujarat Themis Biosyn has reported total income of Rs.93.82 crores for FY 2020-21
Gujarat Themis Biosyn has reported total income of Rs.93.82 crores for FY 2020-21
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
The Government of India has started importing the vital drug Remdesivir from other countries to ease out the shortage of Remdesivir in the country
This oxygen is being provided free-of-cost to several state governments across the country to bring immediate relief to over 1 lakh patients on a daily basis
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
Molnupiravir is an investigational oral antiviral drug currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19
The drug is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer and ovarian, cervical and renal cancer
In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark
The production capacity is now ramped up to 90 lakh vials per month whereas earlier it was 40 lakh vials/month
Subscribe To Our Newsletter & Stay Updated
